Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

Journal of Neurochemistry

Volumn 95, Issue 1, 2005, Pages 68-78

  Zheng, Hailin ^a   Gal, Shunit ^b   Weiner, Lev M ^a   Bar Am, Orit ^b   Warshawsky, Abraham ^a   Fridkin, Mati ^a   Youdim, Moussa B H ^a,b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antioxidant iron chelator; Monoamine oxidase inhibitor; Neuroprotection; Oxidative stress; Parkinson's and Alzheimer's diseases

Indexed keywords

1 (2,6 DICHLOROPHENYL) 3,4 DIHYDRO 6,7 DIMETHOXYISOQUINOLINE; 2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; ANTIOXIDANT; ANTIPARKINSON AGENT; DEFEROXAMINE MESYLATE; HLA 20; HYDROXYL RADICAL; IRON CHELATING AGENT; LIPID PEROXIDE; M 24; M 25; M 29; M 30A; M 30B; M 31; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N PROPARGYLAMINE; OXIDOPAMINE; RASAGILINE; UNCLASSIFIED DRUG; VK 28;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; CELL VIABILITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FENTON REACTION; IC 50; IN VITRO STUDY; LIPID PEROXIDATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; CYSTEINE; DESIGNER DRUGS; HYDROXYL RADICAL; HYDROXYQUINOLINES; IRON CHELATING AGENTS; LIPID PEROXIDATION; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PC12 CELLS; PIPERAZINES; RATS;

ANIMALIA;

EID: 25644461154     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03340.x     Document Type: Article

References (67)

1. Atabay C., Cagnoli C. M., Kharlamov E., Ikonomovic M. D. and Manev H. (1996) Removal of serum from primary cultures of cerebellar granule neurons induces oxidative stress and DNA fragmentation: protection with antioxidants and glutamate receptor antagonists. J. Neurosci. Res. 43, 465-47 5.
2. Ben-Shachar D., Eshel G., Finberg J. P. and Youdim M. B. H. (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441-1444.
3. Ben-Shachar D., Nava Kahana N., Kampel V., Warshawsky A. and Youdim M. (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology. 46, 254-263.
4. Berg D., Grote C., Rausch W. D., Maurer M., Wesemann W., Riederer P. and Becker G. (1999) Iron accumulation in the substantia nigra in rats visualized by ultrasound. Med. Biol. 25, 901-904.
5. Bharath S., Hsu M., Kaur D., Rajagopalan S. and Andersen Julie K. (2002) Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 64, 1037-1048.
6. Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D. E. and Mattevi A. (2004) Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J. Med. Chem. 47, 1767-1774.
7. Blandini F., Armentero M. T., Fancellu R., Blaugrund E. and Nappi G. (2004) Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. 187, 455-459.
8. Burton G. W. and Ingold K. U. (1981) Autoxidation of biological molecules. Antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. J. Am. Chem. Soc. 103, 472-477.
9. Cadet J. L., Katz M., Jackson-Lewis V. and Fahn S. (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476, 10-15.
10. Cherny R. A., Atwood C. S., Xilinas M. E. et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30, 665-676.
11. Chiou T. J. and Tzeng W. F. (2000) The roles of glutathione and antioxidant enzymes in menadione-induced oxidative stress. Toxicology. 154, 75-84.
12. Cohen G. and Kesler N. (1999) Monoamine oxidase and mitochondrial respiration. J. Neurochem. 73, 2310-2315.
13. Desport J. C. and Couratier P. (2002) Oxidative stress in neurodegenerative diseases. Nutr. Clin. Metabol. 16, 253-259.
14. Drukarch B. and van Muiswinkel F. L. (2000) Drug treatment of Parkinson's disease. Time for phase II. Biochem. Pharmacol. 59, 1023-1031.
15. Dunnett S. B. and Bjorklund A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature. 399, A32-A39.
16. Fowler J. S., Logan J., Volkow N. D., Wang G. J., MacGregor R. R. and Ding Y. S. (2002). Monoamine oxidase: radiotracer development and human studies. Methods. 27, 263-277.
17. Gal S., Zheng H., Mati Fridkin M. and Youdim M. B. H. (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. II. in vivo selective brain monoamine oxidase inhibition and neuroprotective activity. J. Neurochem. (in press).
18. Gassen M. and Youdim M. B. H. (1997) The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol. Toxicol. 80, 159-166.
19. 2-induced cell death. Adv. Pharmacol. 42, 320-324.
20. 2 and 6-hydroxydopamine. Mov. Disord. 13, 242-248.
21. Gilgun-Sherki Y., Melamed E. and Offen D. (2001) Oxidative stress induced-neuro-degenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 40, 959-975.
22. Glinka Y., Gassen M. and Youdim M. B. H. (1997) Mechanism of 6-hydroxydopamine neurotoxicity. Adv. Res. Neurodegen. 5, 55-66.
23. Grunblatt E., Mandel S., Maor G. and Youdim M. (2001) Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77, 146-156.
24. Gu M., Owen A. D., Toffa S. E., Cooper J. M., Dexter D. T., Jenner P., Marsden C. D. and Schapira A. H. (1998) Mitochondrial function, GSH and iron in eurodegeneration and Lewy body diseases. J. Neurol. Sci. 158, 24-29.
25. Halliwell B. (1996) Vitamin C: antioxidant or pro-oxidant in vivo? Free Radical Res. 25, 439-454.
26. 2 radicals with nitrones in the ultraviolet photolysis of aqueous hydrogen peroxide solutions. Can. J. Chem. 52, 3549-3553.
27. Huang W., Chen Y., Shohami E. and Weinstock M. (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366, 127-135.
28. Hubalek F., Binda C., Li M., Herzig Y., Sterling J., Youdim M. B., Mattevi A. and Edmondson D. E. (2004) Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J. Med. Chem. 47, 1760-1766.
29. Jeon B. S., Jackson-Lewis V. and Burke R. E. (1995) 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration. 4, 131-137.
30. Kalir A., Sabbagh A. and Youdim M. B. (1981) Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br. J. Pharmacol. 73, 55-64.
31. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J. Q. et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 37, 899-909.
32. Lan J. and Jiang D. H. (1997) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm. 104, 469-481.
33. LaVaute T., Smith S., Cooperman S. et al. (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurode-generative disease in mice. Nat. Genet. 27, 209-214.
34. Levites Y., Weinreb O., Maor G., Youdim M. B. H. and Mandel S. (2001) Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78, 1073-1082.
35. Levites Y., Youdim M. H. B., Maor G. and Mandel S. (2002) Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-κB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 63, 21-29.
36. Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y. and Youdim M. B. H. (2003) Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17, 729-762.
37. Mandel S., Weinreb O., Amit T. and Youdim M. B. (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J. Neurochem. 88, 1555-15 569.
38. Maruyama W., Weinstock M., Youdim M. B., Nagai M. and Naoi M. (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)- aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. 341, 233-236.
39. Mattson M. P. (2004) Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann. N.Y. Acad. Sci. 1012, 37-50.
40. McDowell I. (2001) Alzheimer's disease: insights from epidemiology. Aging. 13, 143-162.
41. Melamed E. and Youdim M. B. H. (1985) Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase. Br. J. Pharmacol. 86, 529-531.
42. Moussaoui S., Obinu M. C., Daniel N., Reibaud M., Blanchard V. and Imperato A. (2000) The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 166, 235-245.
43. Mytilineou C., Radcliffe P., Leonardi E. K., Werner P. and Olanow C. W. (1997) L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68, 33-39.
44. Offen D., Ziv I., Sternin H., Melamed E. and Hochman A. (1996) Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 141, 32-39.
45. Parkinson Study Group. (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561-566.
46. Perry G., Nunomura A., Hirai K. et al. (2002) Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radical Biol. Med. 3, 1475-1479.
47. Przedborski S. and Jackson-Lewis V. R. (2000) ROS and Parkinson's disease: a view to a kill. Oxidative Stress Dis. 5, 273-290.
48. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K. and Youdim M. B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
49. Rukenstein A., Rydel R. E. and Greene L. A. (1991) Multiple agents rescue PC12 cells from serum-free cell death by translation- and transcription- independent mechanisms. J. Neurosci. 11, 2552-2563.
50. Singh S., Khodr H., Taylor M. I. and Hider R. C. (1996) Therapeutic iron chelators and their potential side effects. Biochem. Soc. Symp 61, 127-137.
51. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Munoz-Patino A. M. and Labandeira-Garcia J. L. (2000) Autoxidation and neurotoxicity of 6-hydroxy-dopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. 74, 1605-1612.
52. Stefanini S., Chiancone E., Cavallo S., SaeZ. V., Hall A. D. and Hider R. C. (1991) The interaction of hydroxypyridinones with human serum transferrin and ovotransferrin. J. Inorg. Biochem. 44, 27-37.
53. Thomas C. E., Ohlweiler D. F., Vicki L., Taylor V. and Schmidt C. J. (1997) Radical trapping and inhibition of iron-dependent CNS damage by cyclic nitrone spin traps. J. Neurochem. 68, 1173-1182.
54. Tipton K. F. and Youdim M. B. H. (1983) The assay of monoamine oxidase activity. Methods Biog. Amine Res. 441-465.
55. Van Acker S. A., Van den Berg D. J., Tromp M. N. et al. (1996) Structural aspects of antioxidant activity of flavonoids. Free Radical Biol. Med. 20, 331-342.
56. Warshawsky A., Ben-Shachar D. and Youdim M. B. H. (2000) Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators. International application published under the patent cooperation treaty. Int. Publication Number WO 00/74664, A2.
57. Warshawsky A., Youdim M., Fridkin M., Zheng H. L. and Warshawsky R. (2004) Preparation of neuroprotective iron chelators and pharmaceutical compositions comprising them. Int. Publication Number WO 2004041151, A2.
58. Weinreb O., Bar-Am. O., Amit T., Chillag-Talmor O. and Youdim M. B. (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2. Family members. FASEB. J. 18, 1471-1473.
59. 14C-deprenyl. J. Neural Transm. 43, 199-208.
60. Youdim M. B. H. and Buccafesco J. (2005) Multi-functional drugs for various CNS. Trends Pharmac. Sci. 26, 27-36.
61. Youdim M. B. H. and Weinstock M. (2002a) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech. Aging Dev. 123, 1081-1086.
62. Youdim M. B. H. and Weinstock M. (2002b) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech. Aging Dev. 123, 1081-1086.
63. Youdim M. B., Wadia A., Tatton W. and Weinstock M. (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. N.Y. Acad. Sci. 939, 450-458.
64. Youdim M. B., Fridkin M. and Zheng H. (2004a) Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J. Neural Transm. 111, 1455-1471.
65. Youdim M. B., Stephenson G. and Ben Shachar D. (2004b) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N.Y. Acad. Sci. 1012, 306-325.
66. Zecca L., Youdim M. B., Riederer P., Connor J. R. and Crichton R. R. (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873.
67. Zheng H., Weiner L. M., Bar-Am. O., Epsztejn M., Cabantchik I., Warshawsky A., Youdim M. B. H. and Fridkin M. (2005) Design, synthesis and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in neurodegenerative diseases. Bioorg. Med. Chem. 13, 773-783.